COVID-19 Vaccine UPDATES
Booster dose of covid-19 vaccine authorized for individuals in high-risk categories
Recommended time frames
The recommended time frame for administering the Pfizer and Moderna third dose for the immunocompromised population is at least 28 days after the second shot.
The booster for high-risk individuals should be administered at least six months after the second shot.
COVID- 19 Vaccine in pregnancy is it safe?
CDC strongly recommends COVID-19 vaccination either before or during pregnancy, because the benefits of vaccination for both pregnant persons and their fetus/infant outweigh known or potential risks. Getting a COVID-19 vaccine can prevent severe illness, death, and pregnancy complications related to COVID-19.
Why do we need booster does for COVID 19 vaccine?
Data suggests that protection from the initial vaccine is declining in some populations who were fully vaccinated.
Booster vaccine is essential for continued protection against the COVID 19 disease for certain high risk population.
FDA VACCINE UPDATE 10/20/21.
FDA expands the use of booster dose for COVID 19 vaccine in eligible population.
Single booster dose of the Moderna COVID-19 Vaccine may be administered at least 6 months after completion of the primary series to individuals:
65 years of age and older
18 through 64 years of age at high risk of severe COVID-19
18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2
Moderna-booster is half the dose of the primary series.
Janssen (Johnson and Johnson) COVID-19 Vaccine: Single booster dose
May be administered at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.
MIX AND MATCH any of the available COVID-19 vaccines booster dose in eligible individuals following completion of primary vaccination with a different available COVID-19 vaccine.
Pfizer-BioNTech COVID-19 Vaccine ---
Single booster dose at least 6 months after completion of the primary series to individuals 18 - 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.